900522-85-2

Upstream product

• 799274-04-7 (phenylmethyl) 1-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]-1-cyclopentanecarboxylate 
• 1413936-72-7 benzyl 1-(((3R)-1-aza-6-(2,3-dihydro-2,2,4,6,7-pentamethyl-2H-1-benzofuran-5-yl)sulfonylguanidino)-3-(9H-9-fluorenylmethoxycarboxamido)-2-oxohexan-1-yl)cyclopentanecarboxylate 
• 35264-09-6 1-(tert-butoxycarbonylamino)cyclopentanecarboxylic acid 
• 5471-59-0 (phenylmethyl) 1-amino-1-cyclopentanecarboxylate 
• 100-39-0 benzyl bromide 
• 187618-60-6 N-α-[(9H-fluoren-9-ylmethoxy)carbonyl]-N^G-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl)-D-arginine 

Relevant academic research and scientific papers

Binaphthyl-anchored antibacterial tripeptide derivatives with hydrophobic C-terminal amino acid variations

The facile synthesis of seven new dicationic tripeptide benzyl ester derivatives, with hydrophobic group variations in the C-terminal amino acid component, is described. Moderate to good activity was seen against Gram-positive bacteria in vitro. One cyclohexylsubstituted compound 2c was tested more widely and showed good potency (MIC values ranging from 2-4 μg/mL) against antibiotic-resistant strains of Staphylococcus aureus and Enterococci (VRE, VSE), and against Staphylococcus epidermidis.

PEPTIDIC COMPOUNDS

The present invention provides a compound of formula (I), (II), (III) and (IV) as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention.